Sep. 24 at 8:34 PM
$PHGE is progressing through pivotal trials for its fully implanted cochlear implant, Acclaim®, with no serious adverse events reported and 6-month follow-ups underway. The company has laid out a clear post-approval commercialization strategy targeting 30–40 clinical sites and recently strengthened its balance sheet by extinguishing
$32M in debt and raising
$2.5M in a direct offering. While the path to PMA submission extends to 2027, the Breakthrough Device designation and ongoing trial success offer a speculative long-term med-tech opportunity. That said, dilution risk remains high, and the multi-year timeline to revenue makes COCH suitable only for risk-tolerant investors.
